<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0138-6557</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina Militar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. cuban. med. mil.]]></abbrev-journal-title>
<issn>0138-6557</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0138-65572024000300035</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso compasivo de Jusvinza en el tratamiento de un paciente con leptospirosis grave asociada con la reacción de Jarisch Herxeimer]]></article-title>
<article-title xml:lang="en"><![CDATA[Compassionate use of Jusvinza in the treatment of a patient with severe Leptospirosis associated with the Jarisch Herxeimer reaction]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peña Ruiz]]></surname>
<given-names><![CDATA[Rubén Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Venegas Rodríguez]]></surname>
<given-names><![CDATA[Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santana Sánchez]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santiesteban Licea]]></surname>
<given-names><![CDATA[Beatriz Mary]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rittoles Navarro]]></surname>
<given-names><![CDATA[Aliusha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Aguilera]]></surname>
<given-names><![CDATA[Liam Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rittoles Navarro]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ávila Galano]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez-Horta]]></surname>
<given-names><![CDATA[María del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Militar Central &#8220;Dr. Luis Díaz Soto&#8221;  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Ingeniería Genética y Biotecnología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2024</year>
</pub-date>
<volume>53</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0138-65572024000300035&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0138-65572024000300035&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0138-65572024000300035&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: Aproximadamente el 10 % de los casos de leptospirosis humana evolucionan hacia formas graves, entre las que se destaca el síndrome de Weil. Este cuadro puede agravarse por complicaciones asociadas con el uso de antibióticos, como la reacción de Jarisch Herxeimer (RJH). El tratamiento con Jusvinza puede ser una opción para estos estados, mediados por la hiperinflamación.  Objetivo: Describir la evolución clínica de un paciente con leptospirosis y síndrome de Weil, que desarrolló la RJH y fue tratado con Jusvinza.  Caso Clínico:  Paciente masculino, de 50 años, con diagnóstico de leptospirosis, que desarrolló un síndrome de Weil; recibió tratamiento con ceftriaxona y como consecuencia desarrolló el cuadro clínico característico de la RJH, que conllevó al empleo de ventilación mecánica y uso compasivo del fármaco Jusvinza. La mejoría clínica, radiológica y humoral fue evidente a las 48 horas de iniciar el tratamiento.  Conclusiones:  El tratamiento con Jusvinza indujo la disminución de varios biomarcadores de inflamación sistémica y contribuyó a la recuperación del paciente. Estos resultados indican que dicho medicamento pudiera ser una opción efectiva para el tratamiento de las formas graves de Leptospirosis.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Approximately 10% of human leptospirosis cases progress to severe forms, among which Weil syndrome stands out. This condition can be aggravated by complications associated with antibiotics, such as the Jarisch Herxeimer reaction (JHR) that intensifies inflammation. Treatment with Jusvinza may be an option for these states mediated by hyperinflammation.  Objective:  To describe the clinical evolution of a patient with leptospirosis and Weil's syndrome who developed the JHR and was treated with Jusvinza.  Case Report:  50-year-old male patient was diagnosed with Leptospirosis, which progressed to a serious condition and Weil syndrome and received treatment with ceftriaxone, as result he developed JHR, which led to the use of mechanical ventilation and the compassionate use of Jusvinza. The clinical, radiological, and humoral improvement was evident 48 hours after starting treatment.  Conclusions:  Treatment with Jusvinza induced a decrease in several biomarkers of systemic inflammation and contributed to the patient's recovery. These results indicate that Jusvinza may be an effective option for the treatment of severe forms of Leptospirosis and its complications, associated with hyperinflammation.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Jusvinza]]></kwd>
<kwd lng="es"><![CDATA[leptospirosis]]></kwd>
<kwd lng="es"><![CDATA[síndrome de Weil]]></kwd>
<kwd lng="en"><![CDATA[Jusvinza]]></kwd>
<kwd lng="en"><![CDATA[leptospirosis]]></kwd>
<kwd lng="en"><![CDATA[Weil syndrome]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Report of the second meeting of the leptospirosis burden epidemiology reference group]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Geneve ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zamora]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leptospirosis y enfermedad de Weil]]></article-title>
<source><![CDATA[Revista Medica Sinergia]]></source>
<year>2020</year>
<volume>3</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guerrier]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[D'Ortenzio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Jarisch-Herxheimer reaction in leptospirosis: a systematic review]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mauri]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leptospirosis humana: un abordaje epidemiológico desde los factores ambientales]]></article-title>
<source><![CDATA[Rev Cubana Med Gen Integr]]></source>
<year>2017</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>129-38</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Jarisch-Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis]]></article-title>
<source><![CDATA[Am J Trop Med Hyg]]></source>
<year>2017</year>
<volume>96</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-52</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedad de Weil y hepatitis aguda multifactorial. A propósito de un caso]]></article-title>
<source><![CDATA[Rev Gastroenterolog]]></source>
<year>2018</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>253-4</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Barberá]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Darrasse-Jeze]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant induced arthritis]]></article-title>
<source><![CDATA[Autoimmunity]]></source>
<year>2011</year>
<volume>44</volume>
<page-range>471-82</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Corrales]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I Clinical Trial with a Novel Altered Peptide Ligand Derived from Human Heat-Shock Protein 60 for Treatment of Rheumatoid Arthritis: Safety, Pharmacokinetics and Preliminary Therapeutic Effects]]></article-title>
<source><![CDATA[Journal of Clinical Trials]]></source>
<year>2018</year>
<volume>8</volume>
<page-range>2167-0870</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabrales-Rico]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Besada]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Del Carmen]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and validation of a bioanalytical method based on LC-MS/MS analysis for the quantitation of CIGB-814 peptide in plasma from Rheumatoid Arthritis patients]]></article-title>
<source><![CDATA[J Pharm. Biomed. Anal]]></source>
<year>2017</year>
<volume>143</volume>
<page-range>130-40</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venegas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Santana]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Péptido inmunomodulador CIGB-258 para el tratamiento de pacientes graves y críticos con la COVID-19]]></article-title>
<source><![CDATA[Rev Cub Med Milit]]></source>
<year>2020</year>
<volume>49</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Cedeño]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Venegas-Rodriguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bequet-Romero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Santana-Sánchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pentón-Ariaset]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients]]></article-title>
<source><![CDATA[Cell Stress and Chaperones]]></source>
<year>2020</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>515-25</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
